Management of Heart Failure E-Book

• Herausgeber: John Wiley & Sons
• Kategorie: Fachliteratur
• Sprache: Englisch

Seitenzahl: 926

Veröffentlichungsjahr: 2011

Beschreibung

This volume presents a fresh international perspective on current approaches to treating heart failure. An accessible reference for hospital-based specialists, the book provides an update on recent advances in therapeutics and pharmacology, as well as ongoing trials. Four major sections concentrate on a review of screening, assessment and diagnosis; an update on drug treatments; an update on device therapy; and a description of best practice recommendations for managing clinically challenging cases

Leseprobe

Contents

List of contributors

Section 1 Prevention and evaluation of heart failure

1 Preventing heart failure

Introduction

2 Biomarkers in heart failure

Introduction

Biomarkers

Natriuretic peptides

Non-natriuretic peptides of interest in heart failure

ST-2

Adrenomedullin

Troponin

C-reactive protein

Neutrophil gelatinase-associated lipocalin (NGAL)

The future

3 Imaging the failing heart

Scope of the problem

Therapeutic options in heart failure

Diagnostic approach

Patient example illustrating the 5 step imaging approach

General conclusion

Section 2 Treatment modalities

4 Neurohormonal blocking agents in the treatment of patients with left ventricular dysfunction and heart failure

Introduction

Practical approach to treating patients with beta-blockers

Angiotensin-converting enzyme inhibitors (ACEIs)

Practical approach to treating patients with ACE inhibitors

Angiotensin receptor blockers (ARBs)

Practical approach to treating patients with ARBs

Practical approach to treatment of patients with aldosterone antagonists

5 Digoxin, diuretics, and vasodilators in heart failure

Digitalis

Diuretics

6 Management of comorbidity in chronic heart failure

Novel therapeutics for coronary artery disease in heart failure

Management of anemia in patients with heart failure

Renal dysfunction and the cardiorenal syndrome

7 Emerging therapies for heart failure

Introduction

Can heart failure be prevented?

New drugs

Gene transfer

Cell transplantation therapy

Section 3 Device and anti-arrhythmic therapy of heart failure

8 Preventing sudden cardiac arrest in the heart failure patient

Introduction

Pharmacologic therapies to prevent SCA in heart failure

Which heart failure patients benefit from the ICD?

The clinical dilemma: How to use the guidelines

Clinical risk scores may improve risk stratification for SCA

Emerging technologies to improve the risk stratification for SCA

Conclusions

9 Cardiac resynchronization therapy: indications for treatment and strategies for optimizing results

Introduction

The clinical problem: pathophysiology of ventricular dys-synchrony

Dys-synchrony explains the adverse effects of ‘traditional’ RV pacing

The clinical implementation of CRT

Clinical benefits of CRT

Clinical trial evidence to support CRT

Current indications for CRT

The first clinical dilemma — what is “response” to CRT?

The second clinical dilemma — how do we identify responders?

The third clinical dilemma — can we optimize CRT for a given patient?

Other clinical dilemmas in CRT

Cost effectiveness of CRT

Conclusions

10 Treatment of atrial arrhythmias in heart failure patients

Introduction

Epidemiology

Rationale for treatment of atrial arrhythmias

Treatment of atrial arrhythmias in heart failure

Conclusion

11 Devices for following heart failure patients

Introduction

Therapeutic devices as monitors

Heart rate

Arrhythmia burden

Proportion of atrial or ventricular pacing

Heart rate variability

Future monitoring systems

Clinical practice

Conclusions

Section 4 Individualizing treatment of heart failure

12 Recognising and managing the patient with heart failure and preserved ejection fraction

What is diastolic heart failure?

Terminology

Epidemiology of DHF

Recognizing DHF

Pathophysiology of DHF

Management of DHF

13 Treating systolic heart failure

Introduction

Etiology

Classification

Goals of therapy

At-risk for heart failure (stage A)

Patients with cardiac structural abnormalities or remodeling who have not developed HF symptoms (stage B)

Patients with current or prior symptoms of CHF with reduced left ventricular systolic function (stage C): Non-pharmacologic measures

Pharmacologic measures

Management of fluid status

Diuretics

Inhibition of the renin-angiotensin-aldosterone system

Ace-inhibitors

Angiotensin receptor blockers

Aldosterone antagonists

Beta-blockers

Digoxin

Vasoactive agents

Calcium-channel blockers

Drug treatment for supraventricular arrhythmias

Chronic resynchronization therapy and implantable cardioverter defibrillators

Anticoagulants (vitamin K antagonists)

HMG-CoA reductase inhibitors (statins)

Refractory HF requiring specialized interventions (stage D)

Future directions/new therapeutic targets

14 Treatment of acutely decompensated heart failure

Definition and classification of acute heart failure

Epidemiology of acute heart failure (AHF)

Pathophysiology of acute heart failure

Symptoms in acute heart failure

Diagnosis of acute heart failure

Treatment for acute heart failure

Future treatment of acute heart failure

15 Management of advanced heart failure

Definition

Pharmacologic therapy in patients with stage D heart failure

Device management

Surgical options

Special considerations and end of life issues

Conclusion

Index

This edition first published 2010©2010 John Wiley & Sons Ltd

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical, and Medical business with Blackwell Publishing.

Registered office:John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Other Editorial Offices:9600 Garsington Road, Oxford, OX4 2DQ, UK111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services, and for information about how to apply for permission to reuse the copyright material in this book, please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or website may provide or recommendations it may make. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloguing-in-Publication Data

Management of heart failure / edited by Barry H. Greenberg, Denise D. Barnard, Sanjiv M. Narayan, John R. Teerlink.p. ; cm.Includes index.

Summary: “This volume present a fresh international perspective on current approaches to treating heart failure. An accessible reference for hospital-based specialists, the book provides an update on recent advances in therapeutics and pharmacology, as well as ongoing trials. Four major sections concentrate on a review of screening, assessment and diagnosis; an update on drug treatments; an update on device therapy; and a description of best practice recommendations for managing clinically challenging cases.”–Provided by publisher.

ISBN 978-0-470-75379-8 (cloth)

1. Heart failure–Treatment.I. Greenberg, Barry H. II. Barnard, Denise D. III. Narayan, Sanjiv M. IV. Teerlink, John R.[DNLM: 1. Heart Failure–therapy. WG 370 M2658 2010]RC685.C53M282 2010616.1’2025–dc22

2010025382

A catalogue record for this book is available from the British Library.

eBook ISBN: 978-0-470-66941-9Wiley Online Library ISBN:978-0-470-66940-2

List of contributors

Philip B. Adamson, The Heart Failure Institute at Oklahoma Heart Hospital, Oklahoma City, Oklahoma, USA

Denise D. Barnard, Division of Cardiology, University of California, San Diego, California, USA

Jeroen J. Bax, Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

John G.F. Cleland, Castle Hill Hospital, University of Hull, Kingston-upon-Hull, East Riding of Yorkshire, UK

Jacques Clémenty, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

D. Wyn Davies, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Ruchika Dutta, Division of Cardiology, University of California, San Diego, California, USA

Justin A. Ezekowitz, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada

Ronald Freudenberger, Division of Cardiology, Penn State College of Medicine, Allentown, Pennsylvania, USA

Barry H. Greenberg, Division of Cardiology, University of California, San Diego, California, USA

Michel Haïssaguerre, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Mèléze Hocini, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Amir Jadidi, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Pierre Jaïs, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Sebastien Knecht, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Dawn Lombardo, Division of Cardiology, University of California, Irvine Medical Centre, Orange, California, USA

Alan S. Maisel, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System, and University of California, San Diego, California, USA

Seiichiro Matsuo, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Michael A. McDonald, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada

Shinsuke Miyazaki, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Sanjiv M. Narayan, University of California and Veterans Affairs Medical Center, San Diego, California, USA

Isabelle Nault, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Mark D. O’Neill, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Andrej Pernat, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Vijay U. Rao, Division of Cardiology, School of Medicine, University of California, San Francisco, California, USA

Margaret M. Redfield, Mayo Clinic and Foundation, Cardiorenal Laboratory, Rochester, Minnesota, USA

Thomas K. Ro, Division of Cardiology, University of California, San Diego, California, USA

Frédéric Sacher, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Leo Slavin, Division of Cardiology, University of California, San Diego, California, USA

John R. Teerlink, Section of Cardiology, San Francisco Veterans Affairs Medical Center; School of Medicine, University of California, San Francisco, California, USA

Nico R. Van de Veire, Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Matthew Wright, Hôpital Cardiologique du Haut-Lévêque and the Université Victor Segalen Bordeaux II, Bordeaux, France and The Cardiothoracic Centre, St. Thomas’ Hospital, London, UK

Section 1 Prevention and evaluation of heart failure